Abstract
Background: Microtubules act as a useful and strategic molecular target for various anticancer drugs that binds to its distinct sites in tubulin subunits and inhibits its polymerization and ultimately leads to cell death. Moreover, numerous reports highlight the cytotoxic effects of constraint Combretastatin analogs and thiazolidinone derivatives.
Objective: Therefore, the present study investigates the potential of thiazolidinone constraint combretastatin analogs as tubulin inhibitors.
Method: By incorporating silica supported fluroboric acid, a series of thiazolidinone constraint combretastatin analogs were synthesized in a microwave reactor under solvent free conditions. To optimize the reaction conditions, the detailed investigation was done for the catalytic influence of HBF4-SiO2. All the synthesized analogs were assessed for in-vitro cytotoxicity against THP-1, COLO-205, HCT-116 and A-549 human cancer cell lines. Top hits were further examined for their tubulin polymerization inhibition and their effect on microtubule assembly. The significant cytotoxicity and tubulin polymerization inhibition of the most potent structure was further rationalized by molecular modelling studies.
Results: The results stated that CS-2, CS-3 and CS-20 possessed significant cytotoxic potential with the IC50 values ranging from 1.21 to 5.50 μM against THP-1, COLO-205, HCT-116 human cancer cell lines. Established structure activity relationship revealed that the nature of Ring A substantially influences the cytotoxic potential of the compounds. Placement of methoxy substituents on the phenyl ring (Ring A) was found to be the most preferred structural feature. Compound CS-2 was found to considerably inhibit the tubulin polymerization (IC50 value 2.12 μM) and caused disruption of microtubule assembly as demonstrated by immunoflourescence technique. In molecular modelling studies, CS-2 exhibited various hydrophobic as well as hydrogen bonding interactions at colchicine binding site and was found to be stabilized in this cavity.
Conclusion: This work provides an efficient methodology for the synthesis of antitubulin thiazolodinonecombretastatin hybrids.
Keywords: Thiazolidinones, combretastatins, catalyst, microwave, cytotoxic, antitubulin, docking.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies
Volume: 17 Issue: 2
Author(s): Sahil Sharma, Manish Kumar Gupta, Ajit Kumar Saxena and Preet Mohinder Singh Bedi
Affiliation:
Keywords: Thiazolidinones, combretastatins, catalyst, microwave, cytotoxic, antitubulin, docking.
Abstract: Background: Microtubules act as a useful and strategic molecular target for various anticancer drugs that binds to its distinct sites in tubulin subunits and inhibits its polymerization and ultimately leads to cell death. Moreover, numerous reports highlight the cytotoxic effects of constraint Combretastatin analogs and thiazolidinone derivatives.
Objective: Therefore, the present study investigates the potential of thiazolidinone constraint combretastatin analogs as tubulin inhibitors.
Method: By incorporating silica supported fluroboric acid, a series of thiazolidinone constraint combretastatin analogs were synthesized in a microwave reactor under solvent free conditions. To optimize the reaction conditions, the detailed investigation was done for the catalytic influence of HBF4-SiO2. All the synthesized analogs were assessed for in-vitro cytotoxicity against THP-1, COLO-205, HCT-116 and A-549 human cancer cell lines. Top hits were further examined for their tubulin polymerization inhibition and their effect on microtubule assembly. The significant cytotoxicity and tubulin polymerization inhibition of the most potent structure was further rationalized by molecular modelling studies.
Results: The results stated that CS-2, CS-3 and CS-20 possessed significant cytotoxic potential with the IC50 values ranging from 1.21 to 5.50 μM against THP-1, COLO-205, HCT-116 human cancer cell lines. Established structure activity relationship revealed that the nature of Ring A substantially influences the cytotoxic potential of the compounds. Placement of methoxy substituents on the phenyl ring (Ring A) was found to be the most preferred structural feature. Compound CS-2 was found to considerably inhibit the tubulin polymerization (IC50 value 2.12 μM) and caused disruption of microtubule assembly as demonstrated by immunoflourescence technique. In molecular modelling studies, CS-2 exhibited various hydrophobic as well as hydrogen bonding interactions at colchicine binding site and was found to be stabilized in this cavity.
Conclusion: This work provides an efficient methodology for the synthesis of antitubulin thiazolodinonecombretastatin hybrids.
Export Options
About this article
Cite this article as:
Sharma Sahil, Gupta Kumar Manish, Saxena Kumar Ajit and Bedi Singh Preet Mohinder, Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (2) . https://dx.doi.org/10.2174/1871520615666160504093904
DOI https://dx.doi.org/10.2174/1871520615666160504093904 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on MicroRNA-Induced Pluripotent Stem Cell Generation
Recent Patents on Regenerative Medicine High Throughput Genetic Screening for the Detection of Hereditary Nonpolyposis Colon Cancer (HNPCC) Using Capillary Electrophoresis
Combinatorial Chemistry & High Throughput Screening Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Nano Drug Delivery in Treatment of Oral Cancer, A Review of the Literature
Current Drug Targets Comparative Analysis of Serial and Parallel Fusion on Texture Features for Improved Breast Cancer Diagnosis
Current Medical Imaging An Overview of the Design, Development and Applications of Biodegradable Stents
Drug Delivery Letters Genetic Analysis of CYP2D6 Polymorphism in Indian Populations and its Pharmacogenetic Implications
Current Pharmacogenomics and Personalized Medicine Topical Calcineurin Inhibitors, Pimecrolimus and Tacrolimus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Longevity Depends on a Balance Between Proinflammatory and Anti-Inflammatory Factors: Use of Tcms and Natural Products
Current Drug Discovery Technologies Immune Dysfunction in Chronic Lymphocytic Leukemia: The Role for Immunotherapy
Current Pharmaceutical Design Plant-Derived Bioactive Compounds Produced by Endophytic Fungi
Mini-Reviews in Medicinal Chemistry Isolation and Characterization of a Trypsin-Chymotrypsin Inhibitor from the Seeds of Green Lentil (Lens culinaris)
Protein & Peptide Letters Fabrication of Multi-functionalized Gold Nanoparticles and the Application to Electrochemical Detection of Nitrite
Current Nanoscience Mechanism of Conjugated Imine and Iminium Species, including Marine Alkaloids: Electron Transfer, Reactive Oxygen Species, Therapeutics and Toxicity
Current Bioactive Compounds Diversity of Anticancer and Antimicrobial Compounds from Lichens and Lichen-derived Fungi: A Systematic Review (1985-2017)
Current Organic Chemistry PET Tracers Based on 86Y
Current Radiopharmaceuticals Unravelling Radicals Reactivity Towards Carbon Nanotubes Manipulation/Functionalization
Current Organic Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design